X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, the company will utilize Deciphera's pipeline and approved products, which include Qinlock (ripretinib), indicated for treating fourth-line gastrointestinal stromal tumors.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ono Pharmaceutical
Deal Size: $2,400.0 million Upfront Cash: $2,400.0 million
Deal Type: Acquisition April 29, 2024
Details:
Under the terms of the agreement, GENESIS Pharma will exclusively commercialize Qinlock (ripretinib) for the treatment of fourth-line gastrointestinal stromal tumor.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: GENESIS Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 12, 2024
Details:
DCC-3014 (vimseltinib) is an oral, switch control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1R by exploiting unique features of the switch control region that regulates kinase conformational activation.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Product Name: DCC-3014
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
Qinlock (ripretinib), recently approved in Singapore, is an orally administered switch-control kinase inhibitor developed for the treatment of GIST. Ripretinib improves GIST treatment by inhibiting the full spectrum known mutations in KIT and PDGFRA.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2023
Details:
Qinlock (ripretinib) is an orally administered switch-control kinase inhibitor developed for the treatment of gastrointestinal stromal tumor, or GIST. Ripretinib improves GIST treatment by inhibiting the full spectrum known mutations in KIT and PDGFRA.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
DCC-3014 (vimseltinib) is an oral, switch control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1R by exploiting unique features of the switch control region that regulates kinase conformational activation.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Product Name: DCC-3014
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
Deciphera intends to use the proceeds to fund its planned Phase 3 INSIGHT study of QINLOCK versus sunitinib, to fund the development of DCC-3014 (vimseltinib), including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Product Name: DCC-3014
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $143.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 24, 2023
Details:
Qinlock (ripretinib) is a switch-control tyrosine kinase inhibitor that was engineered to broadly inhibit KIT and PDGFRA mutated kinases, involved in GIST, by using a dual mechanism of action that regulates the kinase switch pocket and activation loop.
Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
Deciphera intends to use the net proceeds from the offering to fund the development of DCC-3014 (vimseltinib), including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients currently underway.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Product Name: DCC-3014
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 19, 2023
Details:
Deciphera intends to use the net proceeds from the offering to fund the development of DCC-3014 (vimseltinib), including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients currently underway.
Lead Product(s): Vimseltinib
Therapeutic Area: Oncology Product Name: DCC-3014
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 18, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
